Symbols

QDEL

QuidelOrtho·NASDAQ

--(--)

QDEL fundamentals

QDEL Q4 2025 Earnings

QuidelOrtho (QDEL) released its earnings on Feb 11, 2026: revenue was 723.60M (YoY +2.23%), beat estimates; EPS was 0.46 (YoY -26.98%), beat estimates.

Revenue / YoY

723.60M

+2.23%

EPS / YoY

0.46

-26.98%

Report date

Feb 11, 2026

QDEL Earnings Call Summary for Q4,2025

2025 Financial Success: $2.73B revenue, 22% EBITDA margin, $597M adjusted EBITDA.
Labs Growth Engine: 6% annual growth, clinical chemistry and immunoassay expansion.
Cost Savings Impact: $140M savings, 5% opex reduction, 240bps margin expansion.
2026 Outlook: $2.7B-$2.9B revenue, $630M-$670M EBITDA, $140M free cash flow.
LEX Launch: FDA clearance nearing, 2026 launch with minimal near-term revenue.
China Growth: Low single digits guided for 2026, offsetting VBP uncertainty.
R&D Momentum: VITROS 450, new platforms, and Results Manager middleware driving innovation.

Earnings

EPS

Revenue

Revenue & Expenses

QDEL has released its 2025 Q4 earnings report, with revenue of 723.60M, reflecting a YoY change of 2.23%, and net profit of -130.70M, showing a YoY change of 26.74%. The Sankey diagram below clearly presents QDEL's revenue sources and cost distribution.

Key Indicators

QuidelOrtho (QDEL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

QuidelOrtho (QDEL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

QuidelOrtho (QDEL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

QuidelOrtho (QDEL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown